熱門資訊> 正文

Tiziana开始测试foralumab治疗多系统萎缩

2025-08-11 21:29

Shares of Tiziana Life Sciences (NASDAQ:TLSA) rose after the FDA approved the mid-stage trial initiation of its lead candidate, intranasal foralumab, in patients with multiple system atrophy.
The stock is up about 8% premarket.
The phase 2a study will be a six‑month trial and will evaluate the effects of intranasal foralumab on microglial activation and safety in patients with multiple system atrophy, a neurodegenerative disorder.

More on Tiziana Life Sciences

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting
Seeking Alpha’s Quant Rating on Tiziana Life Sciences
Historical earnings data for Tiziana Life Sciences
Financial information for Tiziana Life Sciences

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。